---
document_datetime: 2023-09-21 17:19:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/brineura-epar-all-authorised-presentations_en.pdf
document_name: brineura-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6392316
conversion_datetime: 2025-12-24 01:19:57.670107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration      | Immediate Packaging   | Content (concentration)                           | Pack size        |
|------------------|-------------------|------------|-----------------------|------------------------------|-----------------------|---------------------------------------------------|------------------|
| EU/1/17/1192/001 | Brineura          | 150 mg     | Solution for infusion | Intracerebroventr icular use | vial (glass)          | Solution: 5 ml (30 mg/ml) + Flushing solution 5ml | 2 vials + 1 vial |